Plain-English translation of NCT04956445 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is collecting virus samples and blood from people who have COVID-19 or have recovered from it. Researchers want to track how the virus is changing over time and understand which patients are at highest risk of severe illness. They also want to learn about long-term health problems that may develop after COVID-19 infection.
COVID-19 treatments may need to change as the virus evolves, and doctors need better information about which patients are most at risk so they can treat them earlier and more effectively. This study will also help researchers understand and prepare for long-term complications from COVID-19 infection.
You likely qualify if…
You likely don't qualify if…
If you're currently sick with COVID-19, the study team will ask you or your family about joining and explain the study. If you agree, they'll collect a blood sample and information about your health and any medications you're taking. If you've already recovered from COVID-19, you'll donate a blood sample once. The study team will also follow your health over time to track any long-term effects from the infection.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Centers for Disease Control and Prevention, Gilead Sciences
Enrollment target
~2,000 participants
Started
March 2020
Primary completion
December 2027
Age range
6 Months – 120 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dahlene Fusco, MD, PhD
Tulane University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.